Author(s)

Fumihiko Hirai, Eiko Inamasu, Gouji Toyokawa, Tsukihisa Yoshida, Kaname Nosaki, Tomoyoshi Takenaka, Masafumi Yamaguchi, Mitsuhiro Takenoyama, Takashi Seto, Yukito Ichinose

Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan.

Pemetrexed is an antimetabolic agent and is well-known as a potent inhibitor of thymidylate synthase (TS). It also inhibits dihydrofolate reductase (DHFR) and glycinamide ribonucleotide formyl transferase (GARFT). We reported an intriguing case in which a non-small cell lung cancer patient who was refractory to pretreatment with S-1, a strong TS inhibitor, showed good response to pemetrexed treatment.

Pemetrexed, S-1, Thymidylate Synthase

Hirai, F. , Inamasu, E. , Toyokawa, G. , Yoshida, T. , Nosaki, K. , Takenaka, T. , Yamaguchi, M. , Takenoyama, M. , Seto, T. and Ichinose, Y. (2014) Good Response to Pemetrexed after Treatment Failure with Another Thymidylate Synthase Inhibitor in Lung Adenocarcinoma: A Case Report. Journal of Cancer Therapy, 5, 766-768. doi: 10.4236/jct.2014.58085.